<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361776</url>
  </required_header>
  <id_info>
    <org_study_id>2011/4-31/2</org_study_id>
    <nct_id>NCT01361776</nct_id>
  </id_info>
  <brief_title>Humoral Response to Tick-borne Encephalitis Vaccine in Elderly</brief_title>
  <official_title>Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sormland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sormland County Council, Sweden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibody titers after tick-borne encephalitis (TBE) vaccination are less in elderly and
      vaccination breakthroughs are more common in this age group. This has prompted Swedish
      authorities to recommend an additional dose in the initial vaccination schedule (= 0+30+90
      days instead of the usually recommended 0+30 days. The investigators intend to evaluate this
      regime.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The risk for TBE increases in Sweden. Together with an increased awareness of the possibility
      to acquire protection by vaccination, this has led to an increase in the number of doses of
      the vaccine distributed in Sweden each year -now being approximately 400.000. The first year,
      two doses with an interval of 1 month is recommended for the general population, followed by
      a third dose approximately one year later and an additional booster dose three years after
      the third.

      Recent studies show that the antibody titers against TBE are substantially less in an older
      population. This is in line with the present recommendation from Austria that booster
      intervals should be shortened to 3 years in the age group 60+. It is also in line with a
      report of vaccination failures where 13/27 patients were older than 60 years According to a
      study by Jilkowa et al, 18 % (38/185) in the age group 60+ did not achieve putative levels of
      antibody titers after the first two doses. Therefore, the manufacturer of Encepur recommends
      a total of three doses to this age group using the same regimen as with &quot;accelerated
      vaccination schedule (0+7+21 days). Unfortunately, GMT (geometrical mean of titers) after 3
      doses with the accelerated schedule are not superior to 2 doses given at 0+30 days.

      The manufacturer of FSME-immun instead recommends that serology should be checked one month
      after the second dose and that a third dose should be given if titers are not sufficient
      (0+30+60 days). Unfortunately, determinations of titers in a large number of samples put
      severe strain on logistics and is not feasible in Sweden.

      In order to try to improve immunity in the age group 60+ , the Department of Communicable
      Disease Control and Prevention in Stockholm therefore recommends a third dose two months
      after the first two doses to the age group 60+ (0+30+60 days).

      Study design. The investigators intend to give FSME-immune to 3 groups with varying
      vaccination schedules ( 0+7+21, 0+30 or 0+30+90. 50 participants will be randomized to each
      group. Half of them will be between 50-59 years and half will be at least 60 years old. A
      younger age group (50 participants between 18-49 years) will serve as controls and will be
      given FSME-immune according to standard recommendations (0+30 days).

      Serum samples (10 ml of blood) will be obtained at five times: 0,60,120,360 and 400 days
      after first dose Samples will be analysed for neutralising antibodies at the Swedish
      institute for Infectious disease control - other options possible.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentration of neutralising antibodies against TBE one month after two or three doses.</measure>
    <time_frame>18 months after the first dose</time_frame>
    <description>Determination of neutralising antibodies one month after completion of the first years vaccination series</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of neutralising antibodies against TBE one month after the dose which will be given a year later</measure>
    <time_frame>18 months after the first dose has been given</time_frame>
    <description>Determination of neutralising antibodies one month after the dose which will be given a year later</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Tick-borne Encephalitis</condition>
  <arm_group>
    <arm_group_label>TBE vaccine at 0+30 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBE vaccine at 0+7+21 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBE vaccinte at 0+30+90 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>younger participants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FSME-immune</intervention_name>
    <description>0.5 ml im as scheduled in the 4 arms</description>
    <arm_group_label>TBE vaccine at 0+30 days</arm_group_label>
    <arm_group_label>TBE vaccine at 0+7+21 days</arm_group_label>
    <arm_group_label>TBE vaccinte at 0+30+90 days</arm_group_label>
    <arm_group_label>younger participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 50 years or more

          -  generally healthy

          -  no immunosuppressive condition

          -  fertile women must use contraceptives

        Exclusion Criteria:

          -  Previous TBE infection

          -  Previously immunized with TBE vaccine

          -  Anaphylactic reaction to egg protein

          -  Any disease or therapy which might suppress the immune response

          -  Vaccination should be delayed if a participant has fever
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lars rombo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Helsingfors</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Eskilstuna</city>
        <zip>631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of infectious diseases</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of infectious diseases</name>
      <address>
        <city>Ã–rebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sormland County Council, Sweden</investigator_affiliation>
    <investigator_full_name>Lars Rombo</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>immune response</keyword>
  <keyword>TBE-vaccine</keyword>
  <keyword>elderly</keyword>
  <keyword>additional doses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Tick-Borne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

